Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBR 1302
- Development stage
- Discontinued
- Lead developer
- Glenmark Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GBR 1302 is a bispecific monoclonal antibody engineered using Glenmark’s BEAT platform. It simultaneously targets the human epidermal growth factor receptor 2 (HER2) on tumor cells and the CD3 complex on T lymphocytes. By binding to both HER2 and CD3, GBR 1302 redirects cytotoxic T cells to kill HER2-expressing cancer cells through immune-mediated lysis. This mechanism is independent of the T cell’s native specificity and has demonstrated potent activity against both high (IHC3+) and equivocal (IHC2+) HER2-expressing tumors—including those resistant to trastuzumab—in preclinical models. The drug has shown a favorable therapeutic window with low off-tumor toxicity in non-cancerous tissues expressing normal levels of HER2. Clinical development focused on metastatic breast cancer and other solid tumors overexpressing HER2[1][5][6][7].
- Other names
- Anti-HER2/Anti-CD3 bispecific monoclonal antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GBR 1302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBR 1302.